The Schizophrenia International Research Society (SIRS) Annual Congress is a global forum dedicated exclusively to schizophrenia research, bringing together leading scientists, clinicians, and drug developers from around the world to advance the understanding, treatment, and prevention of schizophrenia and related disorders.
This year, SIRS 2026 takes place March 25-29 at the Firenze Fiera in Florence, Italy. CRC’s team is looking forward to being part of the conversation.
Schizophrenia remains one of the most complex and underserved areas in CNS drug development – and it’s an area CRC’s team knows well. With 20+ schizophrenia trials and four FDA approvals supported in the indication, CRC is committed to partnering with the innovators working to advance schizophrenia care.
REPRESENTING CRC AT SIRS 2026
Thomas Hochadel, Pharm.D., President & Co-Founder at CRC
Dr. Hochadel brings 30+ years of clinical research experience to SIRS 2026, with a career deeply rooted in schizophrenia and CNS drug development. Over that time, Dr. Hochadel has played integral roles in 30+ schizophrenia clinical trials and supported six FDA approvals, three of which were completed at CRC.
As a co-founder of CRC, Dr. Hochadel is known for advancing CNS trials, cultivating long-term site relationships, and championing open collaboration across the field. At SIRS 2026, Dr. Hochadel will be connecting with peers and discussing what it takes to move schizophrenia research forward.
SCHEDULE A CONVERSATION
If you’ll be in Florence for SIRS 2026, CRC’s team would welcome the opportunity to connect. Whether you’re navigating a complex schizophrenia program, exploring CRO partnerships, or simply want to talk CNS, Dr. Hochadel is looking forward to the conversation.
